Tillotts Pharma AG
Tillotts Pharma AG, headquartered in Switzerland (CH), is a prominent player in the pharmaceutical industry, specialising in gastrointestinal therapies. Founded in 2000, the company has established itself as a leader in developing innovative treatments for conditions such as inflammatory bowel disease and irritable bowel syndrome. With a strong presence in Europe and expanding operations in other regions, Tillotts Pharma is renowned for its unique product offerings, including the well-regarded 5-ASA compound, which sets it apart in the market. The company’s commitment to research and development has led to significant milestones, enhancing its reputation for quality and efficacy. Recognised for its contributions to patient care, Tillotts Pharma AG continues to solidify its market position through strategic partnerships and a focus on unmet medical needs, making it a trusted name in gastrointestinal health.
DitchCarbon Score
How does Tillotts Pharma AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tillotts Pharma AG's score of 28 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Tillotts Pharma AG's reported carbon emissions
Tillotts Pharma AG, headquartered in Switzerland (CH), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Zeria Pharmaceutical Co., Ltd., which may influence its climate-related initiatives and reporting practices. As of now, Tillotts Pharma AG has not established any documented reduction targets or commitments under the Science Based Targets initiative (SBTi) or other climate pledges. This lack of specific targets suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the context of the pharmaceutical industry, it is increasingly important for companies like Tillotts Pharma AG to adopt robust climate commitments and transparent emissions reporting to align with global sustainability goals. The cascading of data and initiatives from Zeria Pharmaceutical Co., Ltd. may provide a framework for future climate action, but specific details on emissions and reduction strategies remain unavailable at this time.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Tillotts Pharma AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
